Solutions for Healthcare Providers

iStent inject® W

iStent inject® W is indicated for use in conjunction with cataract surgery for the reduction of IOP in adult patients with mild to moderate primary open-angle glaucoma.

Contact Representative
Two iStent inject® W devices that use trabecular micro-bypass technology.
Two iStent inject® W devices that use trabecular micro-bypass technology.

Key Advantages to Using Glaukos Trabecular Micro-Bypass Device During Cataract Surgery Include:

200+ Peer-Reviewed Publications

iStent inject® W is the gold standard in micro-invasive glaucoma surgery (MIGS), continuing the legacy of excellence set throughout 20 years of iStent® devices. It’s backed by the most robust, diverse, and longest-term body of clinical evidence for any MIGS procedure available today, driven through clinical rigor and integrity.

Optimized Outflow

Two multi-directional stents designed to restore natural outflow

Clinically Proven

Significant IOP reduction across a wide range of clinical studies 1 2

Procedural Elegance

Predictability and precision meet the needs of your practice

Proven Safety

Safety profile similar to cataract surgery alone1

All with the Exceptional Customer Support You’ve Come to Expect from Glaukos

iStent inject® Trabecular Micro-Bypass insertion illustration.

Mechanism of Action: Restoring the Natural Outflow Pathway

iStent inject® Trabecular Micro-Bypass insertion illustration.

iStent inject® W creates two patent bypass pathways through the trabecular meshwork—the main source of resistance for aqueous outflow—resulting in multi-directional flow through Schlemm’s canal. And it is one of the smallest medical devices known to be implanted in the human body. Together, these unique advantages are designed to provide exceptional results in a truly micro-invasive approach.

iStent inject® Trabecular Micro-Bypass insertion illustration.
The inferonasal-quadrant showing two Glaukos trabecular micro-bypass stents are placed two to three clock hours apart.

Optimize Outflow with the iStent inject® W

The inferonasal-quadrant showing two Glaukos trabecular micro-bypass stents are placed two to three clock hours apart.

Glaukos trabecular micro-bypass stents are placed two to three clock hours apart. The stents are multi-directional and together, they are designed to deliver access to multiple collector channels and arcs of flow that can span five to six clock hours. The stents may also re-establish flow in previously dormant outflow channels.3

The inferonasal-quadrant showing two Glaukos trabecular micro-bypass stents are placed two to three clock hours apart.

Prioritizing Safety and Outcomes

Putting the primary emphasis on maximizing benefits and minimizing long-term complications, iStent inject® W is designed to support optimal outcomes after cataract surgery and much more:

  • Micro-invasive and astigmatically-neutral
  • Utilizes the conventional outflow pathway
  • Leaves natural anatomy intact, preserving the potential for future treatment options, including drug delivery devices
  • Minimally traumatic to delicate eye tissue and spares conjunctival tissue
  • Reduces risk of hypotony by utilizing the natural episcleral venous pressure
  • Offers postoperative care profile similar to cataract surgery

Exceptional Elegance. Advanced Innovation

The iStent inject® W System is engineered to provide an enhanced surgical experience and ensure confident delivery, for every procedure. With a streamlined injector system and next-generation stent design, featuring a wide flange at its base, iStent inject® W is designed to optimize stent visualization and placement, enhance procedural predictability, and increase peace of mind.

Three close ups: iStent inject W stents, insertion tube with window, and insertion sleeve tip.
The iStent delivery handpiece - the injector system.

Explore Patient Resources for Glaucoma
Treatment Options

iStent inject® W is indicated for use in adult patients with mild-to-moderate open-angle glaucoma that are undergoing cataract surgery. By taking advantage of this one-time opportunity, you may be able to provide your patients with better IOP control and a reduced dependence on medication.

View Patient Website

Micro Stents. Macro Efficacy.

See the latest clinical data around patient outcomes. iStent inject® W builds on the trabecular micro-bypass technology of iStent inject®, which has demonstrated efficacy across a wide range of clinical studies.

View Clinical Data

Reimbursement Support

Tailor-Made Market Access Solutions

Looking for reimbursement info? GPS (Glaukos Patient Services) provides strategic and trustworthy market access solutions for all Glaukos procedures and products in glaucoma, corneal health, and retinal disease care.

Reimbursement Info

Resources for Healthcare Professionals

Resources to Help You Make Informed Decisions

As a trusted industry leader – and the corporate founder of MIGS – we have the experience, tools, and training to make integration easy, starting with the resources we make available to you.

View Resources

Contact Us Today to Integrate iStent inject® W Into Your Practice

Complete the form to get started with offering iStent inject® W to your patients.

Request More Info

"*" indicates required fields

Address*
Glaukos will use the information you provide on this form to be in touch with you.*
This field is for validation purposes and should be left unchanged.

References

  • Samuelson TW, Sarkisian SR, Lubeck DM, et al. Prospective, randomized, controlled pivotal trial of an ab interno implanted trabecular micro-bypass in primary open-angle glaucoma and cataract. Ophthalmology. Jun 2019;126(6):811-821.
  • Hengerer FH, Auffarth GU, Riffel C, Conrad-Hengerer I. Prospective, non-randomized, 36-month study of second-generation trabecular micro-bypass stents with phacoemulsification in eyes with various types of glaucoma. Ophthalmol Ther. 2018 Dec;7(2):405-415.
  • Data on file, Glaukos Corporation

iDose® TR (travoprost intracameral implant)
Important Safety Information

Dosage And Administration

For ophthalmic intracameral administration. The intracameral administration should be carried out under standard aseptic conditions.

Contraindications

iDose TR is contraindicated in patients with active or suspected ocular or periocular infections, patients with corneal endothelial cell dystrophy (e.g., Fuch’s Dystrophy, corneal guttatae), patients with prior corneal transplantation, or endothelial cell transplants (e.g., Descemet’s Stripping Automated Endothelial Keratoplasty [DSAEK]), patients with hypersensitivity to travoprost or to any other components of the product.

Warnings And Precautions

iDose TR should be used with caution in patients with narrow angles or other angle abnormalities. Monitor patients routinely to confirm the location of the iDose TR at the site of administration. Increased pigmentation of the iris can occur. Iris pigmentation is likely to be permanent.

Adverse Reactions

In controlled studies, the most common ocular adverse reactions reported in 2% to 6% of patients were increases in intraocular pressure, iritis, dry eye, visual field defects, eye pain, ocular hyperaemia, and reduced visual acuity.

Indications And Usage

iDose TR (travoprost intracameral implant) is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).

Please see full Prescribing Information.

You are encouraged to report all side effects to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

You may also call Glaukos at 1-888-404-1644.

iStent infinite® Important Safety Information

Indication for Use

The iStent infinite® Trabecular Micro-Bypass System Model iS3 is an implantable device intended to reduce the intraocular pressure (IOP) of the eye. It is indicated for use in adult patients with primary open-angle glaucoma in whom previous medical and surgical treatment has failed.

Contraindications

The iStent infinite is contraindicated in eyes with angle-closure glaucoma where the angle has not been surgically opened, acute traumatic, malignant, active uveitic, or active neovascular glaucoma, discernible congenital anomalies of the anterior chamber (AC) angle, retrobulbar tumor, thyroid eye disease, or Sturge-Weber Syndrome or any other type of condition that may cause elevated episcleral venous pressure.

Warnings

Gonioscopy should be performed prior to surgery to exclude congenital anomalies of the angle, PAS, rubeosis, or conditions that would prohibit adequate visualization that could lead to improper placement of the stent and pose a hazard.

MRI Information

The iStent infinite is MR-Conditional, i.e., the device is safe for use in a specified MR environment under specified conditions; please see Directions for Use (DFU) label for details.

Precautions

The surgeon should monitor the patient postoperatively for proper maintenance of IOP. Three out of 61 participants (4.9%) in the pivotal clinical trial were phakic. Therefore, there is insufficient evidence to determine whether the clinical performance of the device may be different in those who are phakic versus in those who are pseudophakic.

Adverse Events

The most common postoperative adverse events reported in the iStent infinite pivotal trial included IOP increase ≥ 10 mmHg vs. baseline IOP (8.2%), loss of BSCVA ≥ 2 lines (11.5%), ocular surface disease (11.5%), perioperative inflammation (6.6%) and visual field loss ≥ 2.5 dB (6.6%).

Caution

Federal law restricts this device to sale by, or on the order of, a physician. Please see DFU for a complete list of contraindications, warnings, precautions, and adverse events.

iStent® ISI
iStent inject® ISI
iStent inject® W ISI
iStent inject® W with Infinite Injector Technology ISI
iStent infinite® ISI
iAccess® ISI
iDose® TR ISI

Please Select Your Country

Continue